4P7E image
Deposition Date 2014-03-27
Release Date 2014-11-19
Last Version Date 2024-10-09
Entry Detail
PDB ID:
4P7E
Keywords:
TRANSFERASE
Title:
Triazolopyridine compounds as selective JAK1 inhibitors: from hit identification to GLPG0634
Biological Source:
Source Organism(s):
Homo sapiens (Taxon ID: 9606)
Expression System(s):
Spodoptera frugiperda
Method Details:
Experimental Method:
X-RAY DIFFRACTION
Resolution:
2.40 Å
R-Value Free:
0.26
R-Value Work:
0.20
R-Value Observed:
0.20
Space Group:
P 41
4P7E validation report
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Tyrosine-protein kinase JAK2
Gene (Uniprot):JAK2
Chain IDs:A, B
Chain Length:293
Number of Molecules:2
Biological Source:Homo sapiens
UniProt ID:O60674 Pfam ID:PF07714 EC:2.7.10.2
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
PTR A TYR modified residue
Ligand Molecules
2HB
Primary Citation
Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634.
J.Med.Chem. 57 9323 9342 (2014)
PMID: 25369270 DOI: 10.1021/jm501262q

Abstact

Janus kinases (JAK1, JAK2, JAK3, and TYK2) are involved in the signaling of multiple cytokines important in cellular function. Blockade of the JAK-STAT pathway with a small molecule has been shown to provide therapeutic immunomodulation. Having identified JAK1 as a possible new target for arthritis at Galapagos, the compound library was screened against JAK1, resulting in the identification of a triazolopyridine-based series of inhibitors represented by 3. Optimization within this chemical series led to identification of GLPG0634 (65, filgotinib), a selective JAK1 inhibitor currently in phase 2B development for RA and phase 2A development for Crohn's disease (CD).

Legend

Protein

Chemical

Disease

Primary Citation of related structures
4P7E
Feedback Form
Name
Email
Institute
Feedback